candesartan has been researched along with Abnormalities, Drug-Induced in 6 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report the experience from DIRECT (DIabetic REtinopathy and Candesartan Trials), three placebo-controlled studies designed to examine the effects of an ARB, candesartan, on diabetic retinopathy." | 9.15 | Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. ( Bilous, R; Chaturvedi, N; Fuller, JH; Hainer, JW; Jansson, SO; Klein, R; Malm, A; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2011) |
| " We report the experience from DIRECT (DIabetic REtinopathy and Candesartan Trials), three placebo-controlled studies designed to examine the effects of an ARB, candesartan, on diabetic retinopathy." | 5.15 | Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. ( Bilous, R; Chaturvedi, N; Fuller, JH; Hainer, JW; Jansson, SO; Klein, R; Malm, A; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2011) |
| "A pregnant young woman with a severe migraine is prescribed candesartan, an angiotensin II type 1 receptor antagonist (AT II antagonists)." | 1.36 | Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome. ( Haaland, K, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haaland, K | 1 |
| Porta, M | 1 |
| Hainer, JW | 1 |
| Jansson, SO | 1 |
| Malm, A | 1 |
| Bilous, R | 1 |
| Chaturvedi, N | 1 |
| Fuller, JH | 1 |
| Klein, R | 1 |
| Orchard, T | 1 |
| Parving, HH | 1 |
| Sjølie, AK | 1 |
| Hünseler, C | 1 |
| Paneitz, A | 1 |
| Friedrich, D | 1 |
| Lindner, U | 1 |
| Oberthuer, A | 1 |
| Körber, F | 1 |
| Schmitt, K | 1 |
| Welzing, L | 1 |
| Müller, A | 1 |
| Herkenrath, P | 1 |
| Hoppe, B | 1 |
| Gortner, L | 1 |
| Roth, B | 1 |
| Kattner, E | 1 |
| Schaible, T | 1 |
| Schlaich, MP | 1 |
| Cox, RM | 1 |
| Anderson, JM | 1 |
| Cox, P | 1 |
| Hinsberger, A | 1 |
| Wingen, AM | 1 |
| Hoyer, PF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.[NCT00252733] | Phase 3 | 5,238 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.[NCT00252694] | Phase 3 | 4,717 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.[NCT00252720] | Phase 3 | 1,850 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 178 |
| Placebo | 217 |
An estimate of the slope from fitting a linear regression of log(UAER) over time for each patient. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.510 |
| Placebo | 0.543 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 161 |
| Placebo | 182 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 180 |
| Placebo | 136 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 192 |
| Placebo | 193 |
An estimate of the slope from fitting a linear regression of log(UAER) over time (post-randomisation, yearly assessments) for each patient. (NCT00252694)
Timeframe: From Baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/1000 year (Least Squares Mean) |
|---|---|
| Candesartan | 656 |
| Placebo | 718 |
Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 127 |
| Placebo | 124 |
Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252720)
Timeframe: From baseline to the end of the study, i.e., 5 years
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 140 |
| Placebo | 139 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 110 |
| Placebo | 107 |
An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.569 |
| Placebo | 0.642 |
1 trial available for candesartan and Abnormalities, Drug-Induced
5 other studies available for candesartan and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting | 2010 |
Angiotensin II receptor blocker induced fetopathy: 7 cases.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents | 2011 |
Angiotensin receptor blockade in diabetic women of childbearing potential: an acceptable risk?
Topics: Abnormalities, Drug-Induced; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; D | 2011 |
Defective embryogenesis with angiotensin II receptor antagonists in pregnancy.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Angiotensin Receptor Antagonists; Antih | 2003 |
Angiotensin-II-receptor inhibitors in pregnancy.
Topics: Abnormalities, Drug-Induced; Acute Kidney Injury; Adult; Antihypertensive Agents; Benzimidazoles; Bi | 2001 |